Loading stock data…
$1.00-0.04 (-3.85%)
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
Tvardi Therapeutics, Inc. in the Healthcare sector is trading at $1.00 with a market capitalization of $23M. Wall Street consensus targets $9.25 (8 analysts), implying a +825.0% move over the next 12 months. The stock is currently near its 52-week low of $0.93, remaining 66.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.63M↑ | -$7.05M↑ | -$7.59M↓ | -$5.94M↑ | -$8.87M |
| Net Income | -$6.46M↑ | -$6.80M↑ | -$7.28M↓ | -$5.53M↓ | $4.17M |
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferativ...